STAT3 and colorectal cancer: Four ongoing clinical trials were found, involving tocilizumab, an anti-IL6Rα antibody with favorable results in preclinical studies [31, 33], and napabucasin, a STAT3 inhibitor that is also under investigation in colorectal cancer [63].